January 3, 2012

OMP Research

Provectus circulated OneMedPlace Research's profile on the company.

As tends to be the case with buy-side (or pseudo buy-side, in the case of OMP) research, the material contain more declarative comments than their brethren and sistren on the sell-side (recall Dr. Jen's update in early December). It is a good read.

If you already have not received it directly from Provectus News (sign up, by the way), download it here.

No comments:

Post a Comment